𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Botulinum toxin type B de novo therapy of cervical dystonia

✍ Scribed by D. Dressler; H. Bigalke

Publisher
Springer
Year
2005
Tongue
English
Weight
188 KB
Volume
252
Category
Article
ISSN
0340-5354

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

BotB (botulinum Toxin type B): Evaluatio
BotB (botulinum Toxin type B): Evaluation of safety and tolerability in botulinum toxin type A-Resistant cervical dystonia patients (preliminary study)
✍ Dr. Daniel D. Truong; Paul A. Cullis; Christopher F. O'Brien; Martin Koller; Tim 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 314 KB

## Abstract Botulinum toxin (BTX) injection is considered the treatment of choice for patients with cervical dystonia (torticollis). We conducted a pilot, open‐label, dose‐escalation study with BTX type B in 12 patients who no longer responded clinically to injections with BTX type A. At the doses

Comparison of treatment of tardive dysto
Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A
✍ Dr. Allison Brashear; Walter T. Ambrosius; George J. Eckert; Eric R. Siemers 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 337 KB

To compare clinical parameters of patients treated with botulinum toxin type A (BTX) for treatment of idiopathic cervical dystonia (ICD) and for tardive cervical dystonia (TCD), we studied 156 patients (149 with ICD and 7 with TCD) who were treated with serial injections of BTX over 5 years. We hypo

Botulinum toxin type B vs. type A in tox
Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial
✍ Eric J. Pappert; Terry Germanson 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB

## Abstract The objective of this study was to compare efficacy, safety, and duration of botulinum toxin type A (BoNT‐A) and type B (BoNT‐B) in toxin‐naïve cervical dystonia (CD) subjects. BoNT‐naïve CD subjects were randomized to BoNT‐A or BoNT‐B and evaluated in a double‐blind trial at baseline a